Zuranolone in Major Depressive Disorder: Results From MOUNTAIN-A Phase 3, Multicenter, Double-Blind, Randomized,...

Area of Science:

• Neuroscience
• Psychiatry

Background:

• Major Depressive Disorder (MDD) is a prevalent and debilitating mental health condition.
• GABA_A receptor positive allosteric modulators represent a novel therapeutic avenue for MDD.

Purpose of the Study:

• To assess the efficacy and safety of zuranolone, a neuroactive steroid, in treating adults with MDD.
• To evaluate zuranolone's impact on depressive symptom severity over a 14-day treatment period.

Main Methods:

• Phase 3, double-blind, randomized, placebo-controlled MOUNTAIN study.
• Adult outpatients with DSM-5 diagnosed MDD received zuranolone (20 mg or 30 mg) or placebo for 14 days.
• Primary endpoint: Change from baseline in Hamilton Depression Rating Scale (HDRS-17) at day 15.

Main Results:

• The study did not meet its primary endpoint for the 30 mg zuranolone dose versus placebo at day 15.
• Significant rapid improvements in depressive symptoms were observed with 30 mg zuranolone at days 3, 8, and 12.
• The 20 mg dose did not show significant improvement compared to placebo.
• Adverse events were similar between groups; common events included fatigue and somnolence.

Conclusions:

• Zuranolone 30 mg demonstrated rapid antidepressant effects, although the primary endpoint was not achieved.
• Zuranolone was generally well-tolerated in patients with MDD.
• Further investigation may be warranted for specific patient subgroups or dosing strategies.